Breaking News Instant updates and real-time market news.

OXFD

Oxford Immunotec

$12.83

0.27 (2.15%)

, QGEN

QIAGEN

$27.27

-0.17 (-0.62%)

16:07
10/03/16
10/03
16:07
10/03/16
16:07

Oxford Immunotec announces 'favorable' patent litigation decision from U.S court

Oxford Immunotec Global (OXFD) announced that the U.S. District Court for the District of Massachusetts reinstated the kit claims of the Company's patent infringement claims against the defendants, Qiagen (QGEN), Quest Diagnostics (DGX) and Laboratory Corporation of America Holdings (LH), following its review of the Magistrate Judge's Report and Recommendation of August 31, 2016. In issuing its ruling, the District Court rejected Qiagen's arguments that the patents were not valid and permitted the case to proceed on Qiagen's products and its customers' use of them. As a result of the District Court's decision, all claims of the Company's six patents remain at issue and the case will proceed to the next phases of discovery and, ultimately, trial. "We are pleased by the court's decision and, in particular, the reinstatement of the direct infringement claims against Qiagen," said Dr. Peter Wrighton-Smith, Chief Executive Officer of Oxford Immunotec. "Defense of all claims of our patents remains a priority for us and we will continue to pursue such defense vigorously."

OXFD

Oxford Immunotec

$12.83

0.27 (2.15%)

QGEN

QIAGEN

$27.27

-0.17 (-0.62%)

DGX

Quest Diagnostics

$84.07

-0.56 (-0.66%)

LH

LabCorp

$136.29

-1.19 (-0.87%)

  • 26

    Oct

  • 06

    Nov

  • 11

    Nov

OXFD Oxford Immunotec
$12.83

0.27 (2.15%)

06/20/16
PIPR
06/20/16
NO CHANGE
PIPR
Final PAMA rule better than expected, says Piper Jaffray
Piper Jaffray analyst William Quirk says the final Protecting Access to Medicare Act published Friday by Centers for Medicare & Medicaid Services is better than expected. PAMA is delayed until 2018 from 2017 as expected, Quirk tells investors in a research note. Hospital labs will be required to submit private payer rates to CMS, a positive relative to prior expectations, the analyst notes. He views the decision as beneficial for Quest Diagnostics (DGX) and LabCorp (LH). Further, CMS will require labs to submit only in-network rates and out-of-network "final" rates, which is a positive for specialty labs who have in-network rates at or above Medicare including CareDx (CDNA), Genomic Health (GHDX), Myriad Genetics (MYGN), Oxford Immunotec (OXFD) and Veracyte (VCYT), Quirk writes.
06/24/16
PIPR
06/24/16
NO CHANGE
Target $25
PIPR
Overweight
Piper Jaffray positive on Imugen acquisition by Oxford Immunotec
Piper Jaffray analyst William Quirk says the acquisition of Imugen, a clinical laboratory focused on developing and performing specialized testing for tick-borne diseases, by Oxford Immunotec is a "good strategic fit" given call point overlap. Oxford's vision is to leverage the exiting sales force and marketing infrastructure to grow its revenue in the U.S., the analyst tells investors in a research note. Quirck also notes that Oxford has more costs than revenue in GBP and today's GBP/USD movements following the "Brexit" vote could be a net benefit. He reiterates an Overweight rating and $25 price target on Oxford's shares.
07/07/16
PIPR
07/07/16
NO CHANGE
PIPR
New FDA recommendation positive for lab companies, says Piper Jaffray
Piper Jaffray analyst William Quirk says that the FDA has issued draft guidance to streamline its approval process for next-generation sequencing, or NGS, germline tests, which could be a substitute for a Premarket Notification or 510k. The analyst believes streamlined regulatory approaches for NGS tests are a positive for labs with NGS laboratory-developed tests such as CareDx (CDNA), Quest Diagnostics (DGX), Genomic Health (GHDX), LabCorp (LH), Myriad Genetics (MYGN), Natera (NTRA), Oxford Immunotec (OXFD), Sequenom (SQNM), Trovagene (TROV), and Veracyte (VCYT).
QGEN QIAGEN
$27.27

-0.17 (-0.62%)

11/12/15
STFL
11/12/15
INITIATION
STFL
Hold
QIAGEN initiated with a Hold at Stifel
08/01/16
HSBC
08/01/16
UPGRADE
HSBC
Buy
QIAGEN upgraded to Buy from Hold at HSBC
HSBC analyst Keppeler upgraded QIAGEN to Buy and increased its price target to $27 from $20. The analyst is more constructive on improving trends in Academia/Pharma and expects topline growth to accelerate to 7% in 2017 from 1-4% in 2012-2015 from strong growth drivers that include QiaSymphony instrument and the NGS franchise.
05/25/16
PIPR
05/25/16
NO CHANGE
PIPR
Neutral
Piper says QIAGEN may need to change or pull GeneReader if Illumina wins suit
Piper Jaffray analyst William Quirk said patent infringement outcomes are hard to predict, but added that Illumina's (ILMN) win at the Patent Trial and Appeal Board increase its chances to prevail in its recently filed infringement lawsuit against Qiagen (QGEN) related to the GeneReader DNA sequencer. If Illumina does win, Qiagen will need to "drastically" alter the product and/or remove it from the market, said Quirk, who keeps a Neutral rating on Qiagen shares.
11/12/15
11/12/15
INITIATION

On The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: Accuray (ARAY) initiated with a Sell at Citi... Becton Dickinson (BDX) initiated with a Neutral at Citi... Boston Scientific (BSX) initiated with a Buy at Citi... Bruker (BRKR) initiated with a Buy at Stifel... C.R. Bard (BCR) initiated with a Buy at Citi... Cepheid (CPHD) initiated with a Buy at Stifel... CorMedix (CRMD) initiated with a Buy at Rodman & Renshaw... CoreSite Realty (COR) initiated with a Buy at BB&T... Digital Realty (DLR) initiated with a Buy at BB&T... DuPont Fabros (DFT) initiated with a Hold at BB&T... Duke Realty (DRE) initiated with a Hold at BB&T... Edwards Lifesciences (EW) initiated with a Sell at Citi... Electronic Arts (EA) initiated with an Outperform at Oppenheimer... EyeGate (EYEG) initiated with a Buy at Maxim... Glu Mobile (GLUU) initiated with a Perform at Oppenheimer... Integra LifeSciences (IART) initiated with a Buy at Citi... Intuitive Surgical (ISRG) initiated with a Buy at Citi... Mast Therapeutics (MSTX) initiated with a Buy at Maxim... Medgenics (MDGN) initiated with a Buy at Needham... Novocure (NVCR) initiated with a Buy at Evercore ISI... Prologis (PLD) initiated with a Hold at BB&T... QIAGEN (QGEN) initiated with a Hold at Stifel... Rocket Fuel (FUEL) initiated with a Neutral at Boenning & Scattergood... STAG Industrial (STAG) initiated with an Underweight at BB&T... Stryker (SYK) initiated with a Sell at Citi... Tremor Video (TRMR) initiated with an Outperform at Boenning & Scattergood... VOXX (VOXX) initiated with an Outperform at Oppenheimer... Varian Medical (VAR) initiated with a Neutral at Citi... Yahoo (YHOO) initiated with an Outperform at Boenning & Scattergood... YuMe (YUME) initiated with a Neutral at Boenning & Scattergood... Zimmer Biomet (ZBH) initiated with a Sell at Citi.
DGX Quest Diagnostics
$84.07

-0.56 (-0.66%)

09/13/16
CHLM
09/13/16
NO CHANGE
CHLM
LabCorp impact from Quest-Optum collaboration limited, says Craig-Hallum
Craig-Hallum analyst Bill Bonello said the Quest Diagnostics (DGX) and Optum, a division of United Healthcare (UNH), collaboration does not put LabCorp's (LH) revenue at risk. The collaboration does not create any lab benefit management service, or a preferred lab network with Quest at the hub, that would drive business to Quest labs or compete with Labcorp's Beacon LBS lab management business, the analyst wrote. Bonellow said UnitedHealthcare and LabCorp continue to work together to expand the Beacon LBS model to other markets and we would expect to see the Beacon lab network expand to other payors overtime. Also, the analyst said the collaboration does not impact LabCorp's contract with UnitedHealthcare, or UHC, and and has no impact on that contract today and does not imply a change to UHC's contracting strategy going forward. Bonello rates LabCorp a Buy with a $160 price target.
09/09/16
SBSH
09/09/16
INITIATION
Target $86
SBSH
Neutral
Quest Diagnostics initiated with a Neutral at Citi
Citi analyst Ralph Giacobbe started Quest Diagnostics with a Neutral rating and $86 price target. The analyst views the valuation as fair given the questions around growth drivers.
08/31/16
08/31/16
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Under Armour (UA) downgraded to Hold from Buy at Argus by John Staszak, based on his belief that the company will have to make significant investments to expand its business going forward. 2. First Solar (FSLR) downgraded to Hold from Buy at Argus by analysts Stephen Biggar and Jasper Hellweg, citing what they see as the company's lack of earnings visibility. The analysts say that the company's backlog is falling, while it is encountering "intense price competition." 3. Palo Alto Networks (PANW) downgraded to Outperform from Strong Buy at Raymond James by analyst Michael Turits, citing the company's weaker than expected guidance for FY17. Palo guided product growth to 12%-13%, nearly halfway below the consensus estimate of 22%, said Turits, who lowered his price target for the shares to $165 from $180. 4. G-III Apparel (GIII) downgraded to Sell from Hold at Stifel. Despite the recent decline in the stock, its risk/reward ratio is unfavorable given the multiple risks faced by the company, according to Stifel analyst Jim Duffy. 5. Quest Diagnostics (DGX) downgraded to Neutral from Buy at Mizuho. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
09/14/16
ADAM
09/14/16
NO CHANGE
Target $155
ADAM
Buy
LabCorp weakness a buying opportunity, says Canaccord
Canaccord analyst Mark Massaro noted LabCorp (LH) shares sold off yesterday on news that its rival, Quest Diagnostics (DGX), announced a partnership with Optum, a subsidiary of UnitedHealth (UNH). The analyst said LabCorp does not believe Quest can wrestle away UnitedHealth's long-standing lab services contract when it goes up for renewal in 2018. Massaro expects LabCorp to deliver steady quarterly beats and said the company is well positioned to capture its losses in the second half of 2016. Massaro reiterated his Buy rating and $155 price target on LabCorp shares.
LH LabCorp
$136.29

-1.19 (-0.87%)

09/13/16
FBCO
09/13/16
NO CHANGE
FBCO
LabCorp weakness a buying opportunity, says Credit Suisse
09/09/16
SBSH
09/09/16
INITIATION
Target $156
SBSH
Neutral
LabCorp initiated with a Neutral at Citi
Citi analyst Ralph Giacobbe started LabCorp with a Neutral rating and $156 price target. The analyst views the valuation as fair given the questions around growth drivers.

TODAY'S FREE FLY STORIES

PTLA

Portola Pharmaceuticals

$38.25

-1.24 (-3.14%)

13:26
06/23/17
06/23
13:26
06/23/17
13:26
Hot Stocks
Portola Pharmaceuticals to resume trading at 1:35 pm ET »

Portola Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jun

  • 24

    Jun

CHGG

Chegg

$12.44

0.48 (4.01%)

13:25
06/23/17
06/23
13:25
06/23/17
13:25
Recommendations
Chegg analyst commentary  »

Chegg price target raised…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

13:25
06/23/17
06/23
13:25
06/23/17
13:25
General news
Energy Action: Baker-Hughes »

Energy Action:…

VRX

Valeant

$15.58

0.0801 (0.52%)

13:20
06/23/17
06/23
13:20
06/23/17
13:20
Options
Valeant expiring options active Friday »

Valeant expiring options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Aug

$NSD

NASDAQ Market Internals

13:17
06/23/17
06/23
13:17
06/23/17
13:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

13:16
06/23/17
06/23
13:16
06/23/17
13:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CLLS

Cellectis

$23.15

0.25 (1.09%)

13:15
06/23/17
06/23
13:15
06/23/17
13:15
Hot Stocks
Breaking Hot Stocks news story on Cellectis 

Cellectis trading resumes…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

INFY

Infosys

$14.90

0.13 (0.88%)

13:13
06/23/17
06/23
13:13
06/23/17
13:13
Hot Stocks
Infosys says 'committed no wrongdoing, denies all allegations' in NY tax matter »

Infosys issued the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CLLS

Cellectis

$23.15

0.25 (1.09%)

13:08
06/23/17
06/23
13:08
06/23/17
13:08
Hot Stocks
Cellectis to resume trading at 1:15 pm ET »

Cellectis is scheduled to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

PTLA

Portola Pharmaceuticals

$38.25

-1.24 (-3.14%)

13:06
06/23/17
06/23
13:06
06/23/17
13:06
Hot Stocks
Portola Pharmaceuticals announces FDA approval of Bevyxxa »

Portola Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jun

  • 24

    Jun

TRIP

TripAdvisor

$35.74

-0.08 (-0.22%)

13:05
06/23/17
06/23
13:05
06/23/17
13:05
Options
TripAdvisor call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

13:05
06/23/17
06/23
13:05
06/23/17
13:05
General news
Cleveland Fed hawk Mester didn't discuss policy »

Cleveland Fed hawk Mester…

BHI

Baker Hughes

$54.55

0.025 (0.05%)

13:03
06/23/17
06/23
13:03
06/23/17
13:03
Hot Stocks
Baker Hughes reports U.S. rig count up 8 to 941 rigs »

Baker Hughes reports that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

13:00
06/23/17
06/23
13:00
06/23/17
13:00
General news
Treasury Action: upcoming supply should put a floor under short rates »

Treasury Action: upcoming…

RIO

Rio Tinto

$39.32

0.61 (1.58%)

, GLNCY

Glencore

$7.10

0.05 (0.71%)

12:59
06/23/17
06/23
12:59
06/23/17
12:59
Hot Stocks
Rio Tinto to give new Glencore C&A proposal 'appropriate consideration' »

Rio Tinto (RIO)…

RIO

Rio Tinto

$39.32

0.61 (1.58%)

GLNCY

Glencore

$7.10

0.05 (0.71%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CLLS

Cellectis

$23.15

0.25 (1.09%)

12:56
06/23/17
06/23
12:56
06/23/17
12:56
Hot Stocks
Cellectis announces Calyxt filing of registration statement for proposed IPO »

Cellectis S.A. announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

PX

Praxair

$133.62

1.15 (0.87%)

12:50
06/23/17
06/23
12:50
06/23/17
12:50
Options
Call spread in Praxair may add to existing bullish position »

Call spread in Praxair…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SYT

Syngenta

$92.65

0.05 (0.05%)

12:45
06/23/17
06/23
12:45
06/23/17
12:45
Periodicals
Syngenta ordered to pay $217.7M to Kansas farmers in GMO corn case, Reuters says »

A federal jury in Kansas…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MT

ArcelorMittal

$21.21

0.315 (1.51%)

12:45
06/23/17
06/23
12:45
06/23/17
12:45
Options
ArcelorMittal call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

12:45
06/23/17
06/23
12:45
06/23/17
12:45
General news
Breaking General news story  »

Week of 6/23 Baker-Hughes…

EFA

iShares MSCI EAFE Index Fund

$65.14

0.16 (0.25%)

, VEA

Vanguard Europe Pacific ETF

$41.22

0.089 (0.22%)

12:42
06/23/17
06/23
12:42
06/23/17
12:42
Technical Analysis
On The Fly: ETF fund flow highlights »

For the past week there…

EFA

iShares MSCI EAFE Index Fund

$65.14

0.16 (0.25%)

VEA

Vanguard Europe Pacific ETF

$41.22

0.089 (0.22%)

IEFA

iShares Core MSCI EAFE ETF

$60.83

0.135 (0.22%)

EWJ

iShares MSCI Japan Index Fund

$54.04

-0.05 (-0.09%)

EZU

iShares MSCI Eurozone ETF

$40.44

0.1 (0.25%)

IBB

iShares Nasdaq Biotechnology Index

$320.11

4.01 (1.27%)

IVV

iShares Core S&P 500

$246.13

0.53 (0.22%)

SPY

SPDR S&P 500 ETF Trust

$243.37

0.53 (0.22%)

VO

Vanguard Mid-Cap Index Fund

$143.23

0.561 (0.39%)

VTI

Vanguard Total Stock Market ETF

$125.10

0.36 (0.29%)

VUG

Vanguard Growth Index Fund

$128.93

0.421 (0.33%)

HYG

iShares iBoxx $ High Yield Corporate Bond

$88.11

0.265 (0.30%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PTLA

Portola Pharmaceuticals

$38.25

-1.24 (-3.14%)

12:33
06/23/17
06/23
12:33
06/23/17
12:33
Hot Stocks
Portola FDA label cites secondary endpoint instead of Cohort 1 data, tweet says »

Twitter user…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jun

  • 24

    Jun

VIX

Volatility Index S&P 500 Options

12:30
06/23/17
06/23
12:30
06/23/17
12:30
Options
VIX calls outpace puts nearly 5:1 as the index dips below 10 »

VIX calls outpace puts…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CZR

Caesars

$12.55

0.2 (1.62%)

, CACQ

Caesars Acquisition

$19.40

0.15 (0.78%)

12:29
06/23/17
06/23
12:29
06/23/17
12:29
Hot Stocks
Caesars announces effectiveness of S-4 registration statement related to merger »

Caesars Entertainment…

CZR

Caesars

$12.55

0.2 (1.62%)

CACQ

Caesars Acquisition

$19.40

0.15 (0.78%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GLYC

GlycoMimetics

$12.10

-0.03 (-0.25%)

12:28
06/23/17
06/23
12:28
06/23/17
12:28
Conference/Events
GlycoMimetics management to meet with Jefferies »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.